• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

PHAR

Partnership for Health Analytic Research

  • Services
    • Real World Data: Secondary Data Analysis
    • Real World Data: Primary Data Collection
    • Evidence Synthesis
  • Publications
  • Clients
  • Team
  • News
  • Contact

Primary Sidebar

News Categories

  • Presentations & Events
  • Awards & Recognition
  • Publications
  • News & Announcements

Archive

  • 2023
  • 2022
  • 2021
  • 2020

PHAR Medical Record Review Compares Prognosis of RA Patients Treated with Abatacept vs TNFis

PHAR’s Michael S. Broder, MD, MSHS, Eunice Chang, PhD, Sarah N. Gibbs, MPH, and Irina Yermilov, MD, MPH, in collaboration with Bristol-Myers Squibb, conducted a study on real-world treatment patterns of patients with rheumatoid arthritis (RA). The investigators performed a multi-center retrospective medical record review, assessing treatment persistence in adult patients with RA complicated by poor prognostic factors. They found that patients on abatacept, including the subgroup of patients with poor prognostic factors, stayed on treatment longer and had a lower risk of discontinuation due to disease progression than patients on tumor necrosis factor-inhibitors. Their findings were published in the Journal of Health Economics and Outcomes Research and can be read here.

May 19, 2021 | Publications

Partnership for Health Analytic Research

Beverly Hills
Cambridge
San Francisco
info@pharllc.com
310.858.9555
pharllc.com
  • Employment
  • Contact
  • Privacy Policy
Design by Studio Rainwater
© PHAR 2023